2016
| Dec.22.2016 | ONO Enters Into Worldwide OmniAb® Platform License Agreement With Ligand Pharmaceuticals, Inc. (34.6KB) |
| Dec.21.2016 | Revisions of Consolidated Financial Forecasts (86.8KB) |
| Dec.16.2016 | Notice of system (server) maintenance (27.1KB) |
| Dec.02.2016 | OPDIVO® (nivolumab) Intravenous Injection Receives Approval for Supplemental Indication of Relapsed or Refractory Classical Hodgkin Lymphoma in Japan (104KB) |
| Nov.18.2016 | Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma (164KB) |
| Nov.15.2016 | Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer (159KB) |
| Nov.14.2016 | Bristol-Myers Squibb's Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer (192KB) |
| Nov.14.2016 | Amgen Receives Marketing Authorization Approval from European Commission for Parsabiv™ (Etelcalcetide) to Treat Patients with Secondary Hyperparathyroidism (31.8KB) |
| Nov.07.2016 | Announcement on Financial Results for FY2016 2Q |
| Oct.26.2016 | New Results Presented for Opdivo (nivolumab) Demonstrated Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients (177KB) |
| Oct.24.2016 | Filing of Patent Infringement Lawsuit against MSD K.K. (81.5KB) |
| Oct.11.2016 | Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer (149KB) |
| Oct.11.2016 | Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study (151KB) |
| Oct.11.2016 | Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer (167KB) |
| Sep.28.2016 | Amgen Announces Top-line Results from Phase III Kyprolis® (Carfilzomib) CLARION Study in Newly Diagnosed Multiple Myeloma Patients (57.2KB) |
| Sep.21.2016 | European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer (189KB) |
| Sep.07.2016 | ONO Launches KYPROLIS® for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor (80.9KB) |
| Sep.05.2016 | Announcement on posting of Corporate Report 2016 |
| Aug.09.2016 | Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo® (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (82.1KB) |
| Aug.08.2016 | Bristol-Myers Squibb Announces Top-Line Results from CheckMate-026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (294KB) |
| Aug.02.2016 | Announcement on Financial Results for FY2016 1Q |
| Jul.19.2016 | Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (207KB) |
| Jul.14.2016 | Notice Concerning Determination of Details of Issuance of Stock Options (Stock Acquisition Rights) (20.1KB) |
| Jul.12.2016 | Amgen Receives Approval for Kyprolis® (Carfilzomib) For Expanded Indication for the Treatment of Relapsed Multiple Myeloma (49.5KB) |
| Jul.11.2016 | ONO enters into license agreement with Celyad for its allogeneic CAR T-cell therapy (NKR-2) (49.8KB) |
| Jul.06.2016 | European Commission approves ONGENTYS® (opicapone) a novel treatment for Parkinson's disease patients with motor fluctuations (352KB) |
| Jun.29.2016 | Notice of Resolutions Passed at The 68th Ordinary General Shareholders' Meeting |
| Jun.29.2016 | Notice Concerning Issuance of Stock Options (Stock Acquisition Rights) (188KB) |
| Jun.28.2016 | Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer (203KB) |
| Jun.15.2016 | New Data on Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial (167KB) |
| Jun.06.2016 | Promising Response Rates with Opdivo® (nivolumab) Observed In Advanced Form of Bladder Cancer From Phase 1/2 Study CheckMate-032 (167KB) |
| Jun.03.2016 | Amgen Receives Positive CHMP Opinion to Extend Indication of Kyprolis® (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma (49.6KB) |
| Jun.01.2016 | Notice to Convene the 68th Ordinary General Shareholders' Meeting |
| May.25.2016 | Launch of Orencia® SC 125 mg Auto-injector 1 mL for Treatment of Rheumatoid Arthritis (98.6KB) |
| May.24.2016 | Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer (196KB) |
| May.20.2016 | European Commission Approves the First and Only Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma (177KB) |
| May.17.2016 | ONO Enters an Agreement with IDAC Theranostics relating to Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody (75.3KB) |
| May.11.2016 | Announcement on Financial Results for FY2015 |
| May.06.2016 | Revision of Consolidated Financial Forecasts (37.0KB) |
| May.06.2016 | Notice regarding Differences between Non-consolidated Results for the Fiscal year Ended March 31, 2016 and those for the Previous Fiscal Year (55.3KB) |
| Apr.28.2016 | Announcement on Candidates of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers (66.2KB) |
| Apr.19.2016 | Support for Relief Efforts to the Kumamoto Earthquake (25.5KB) |
| Apr.13.2016 | European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer (131KB) |
| Apr.11.2016 | ONO Announces Sales Results of OPDIVO® (Nivolumab), Antineoplastic Agent for Fiscal Year 2015 and its Sales Forecasts for Fiscal Year 2016 (33.8KB) |
| Apr.08.2016 | European Commission Approves Bristol-Myers Squibb's Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma (188KB) |
| Apr.06.2016 | Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma (139KB) |
| Apr.01.2016 | European Medicines Agency Validates Bristol-Myers Squibb's Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients (156KB) |
| Mar.30.2016 | ONO Enters Licensing Agreement with Santen for ONO-9054, FP/EP3 Dual Receptor Agonist (33.5KB) |
| Mar.18.2016 | ONO Submits Supplemental Application of OPDIVO® (Nivolumab) for Additional Indication of Relapsed or Refractory Hodgkin’s Lymphoma (82.7KB) |
| Mar.04.2016 | ONO Announces Stock Split and Partial Amendment to the Articles of Incorporation (27.8KB) |
| Mar.01.2016 | Completion of the new Research Building (The Third Building) in the Minase Research Institute (238KB) |
| Feb.29.2016 | ONO Receives Approval for OPDIVO® (Nivolumab) for a Partial Change in Approved Items for Treatment of Unresectable Melanoma in Japan (49.8KB) |
| Feb.26.2016 | Manufacturing and Marketing Approval of Orencia®SC 125mg Auto-injector 1mL for Rheumatoid Arthritis Treatment (186KB) |
| Feb.12.2016 | Support for Relief Efforts to Southern Taiwan Earthquake (21.8KB) |
| Feb.02.2016 | CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early (144KB) |
| Feb.02.2016 | Announcement on Financial Results for FY2015 3Q |
| Feb.02.2016 | Revision of Consolidated Financial Forecasts (33.9KB) |
| Jan.28.2016 | Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status (197KB) |
| Jan.22.2016 | FDA Approves NEW Kyprolis® (Carfilzomib) COMBINATION THERAPY for the treatment of patients with Relapsed Or Refractory multiple myeloma (25.7KB) |